Cargando…

SGLT2 inhibitors and lower limb complications: an updated meta‐analysis

BACKGROUND: To exam the associations between the use of sodium glucose co-transporter 2 inhibitor (SGLT2i) and the risk of lower limb complications, and to analyze the associated factors. METHODS: Pubmed, Medline, Embase, the Cochrane Center Register of Controlled Trials for Studies and Clinicaltria...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Chu, Zhu, Xingyun, Cai, Xiaoling, Yang, Wenjia, Lv, Fang, Nie, Lin, Ji, Linong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082772/ https://www.ncbi.nlm.nih.gov/pubmed/33910574 http://dx.doi.org/10.1186/s12933-021-01276-9

Ejemplares similares

Correction to: SGLT2 inhibitors and lower limb complications: an updated meta-analysis
por: Lin, Chu, et al.
Publicado: (2021)

Reduction of C-reactive protein, low-density lipoprotein cholesterol, and its relationship with cardiovascular events of different lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials
por: Yang, Wenjia, et al.
Publicado: (2022)

Disparities in efficacy and safety of sodium-glucose cotransporter 2 inhibitor among patients with different extents of renal dysfunction: A systematic review and meta-analysis of randomized controlled trials
por: Hu, Suiyuan, et al.
Publicado: (2022)

The Urinary Glucose Excretion by Sodium–Glucose Cotransporter 2 Inhibitor in Patients With Different Levels of Renal Function: A Systematic Review and Meta-Analysis
por: Hu, Suiyuan, et al.
Publicado: (2022)

The Biological Disease-Modifying Antirheumatic Drugs and the Risk of Cardiovascular Events: A Systematic Review and Meta-Analysis
por: Hu, Suiyuan, et al.
Publicado: (2021)

The Body Weight Alteration and Incidence of Neoplasm in Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
por: Lin, Chu, et al.
Publicado: (2020)

Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus
por: Lin, Chu, et al.
Publicado: (2020)

SGLT2 inhibitors and lower limb complications: the diuretic-induced hypovolemia hypothesis
por: Potier, Louis, et al.
Publicado: (2021)

Non-Insulin Antidiabetes Treatment in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Cai, Xiaoling, et al.
Publicado: (2021)

Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon‐Like Peptide‐1 Receptor Agonist and Sodium‐Glucose Cotransporter‐2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta‐Analysis
por: Hu, Mengdie, et al.
Publicado: (2020)

The association between metabolic parameters and evening chronotype and social jetlag in non-shift workers: A meta-analysis
por: Zhang, Rui, et al.
Publicado: (2022)

Trends in baseline HbA1c and body-mass index in randomised placebo-controlled trials of type 2 diabetes from 1987 to 2022: a systematic review and meta-analysis
por: Hu, Suiyuan, et al.
Publicado: (2023)

The Effect of Physical Activity on Glycemic Variability in Patients With Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Zhu, Xingyun, et al.
Publicado: (2021)

Evaluation of efficacy and safety of glucokinase activators—a systematic review and meta-analysis
por: Yang, Wenjia, et al.
Publicado: (2023)

Hereditary renal glycosuria, diabetes and responses to SGLT2 inhibitor
por: Ren, Qian, et al.
Publicado: (2022)

Meta‐analysis and critical review on the efficacy and safety of alpha‐glucosidase inhibitors in Asian and non‐Asian populations
por: Gao, Xueying, et al.
Publicado: (2017)

Addition of dipeptidyl peptidase‐4 inhibitors to insulin treatment in type 2 diabetes patients: A meta‐analysis
por: Yang, Wenjia, et al.
Publicado: (2017)

Relationship Between Gestational Weight Gain and Pregnancy Complications or Delivery Outcome
por: Yang, Wenjia, et al.
Publicado: (2017)

History of lower-limb complications and risk of cancer death in people with type 2 diabetes
por: Mohammedi, Kamel, et al.
Publicado: (2021)

Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers
por: Gessner, Arne, et al.
Publicado: (2022)

Renoprotective effect of SGLT-2 inhibitors among type 2 diabetes patients with different baseline kidney function: a multi-center study
por: Lin, Fang-Ju, et al.
Publicado: (2021)

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis
por: McGuire, Darren K., et al.
Publicado: (2020)

Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease
por: Shao, Shih-Chieh, et al.
Publicado: (2021)

Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF
por: Bode, David, et al.
Publicado: (2021)

Estimation of atherosclerotic cardiovascular disease risk in type 2 diabetes
por: Cai, Xiaoling, et al.
Publicado: (2022)

Efficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis
por: Cai, Xiaoling, et al.
Publicado: (2018)

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis
por: Li, Hang-Long, et al.
Publicado: (2021)

SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2021)

Comparisons of weight changes between sodium‐glucose cotransporter 2 inhibitors treatment and glucagon‐like peptide‐1 analogs treatment in type 2 diabetes patients: A meta‐analysis
por: Cai, Xiaoling, et al.
Publicado: (2017)

Clinical Characteristics of Young Type 2 Diabetes Patients with Atherosclerosis
por: Yang, Wenjia, et al.
Publicado: (2016)

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2022)

SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
por: Bonora, Benedetta Maria, et al.
Publicado: (2021)

Kidney outcomes using a sustained ≥40% decline in eGFR: A meta‐analysis of SGLT2 inhibitor trials
por: Cherney, David Z. I., et al.
Publicado: (2021)

Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis
por: Kaze, Arnaud D., et al.
Publicado: (2022)

No disparity of the efficacy and all‐cause mortality between Asian and non‐Asian type 2 diabetes patients with sodium–glucose cotransporter 2 inhibitors treatment: A meta‐analysis
por: Cai, Xiaoling, et al.
Publicado: (2017)

Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-Analysis
por: Cai, Xiaoling, et al.
Publicado: (2016)

Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
por: Aroor, Annayya R., et al.
Publicado: (2018)

Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients
por: Hwang, In-Chang, et al.
Publicado: (2020)

External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease
por: Smidt, Lisanne C. A., et al.
Publicado: (2021)

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
por: Nauck, Michael A
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_uhu2dqidnpnomk8s8kdktgs7d6